| Catalog No. | Size | Price (USD) |
| N16-12CG-10 | 10 µg | $500.61 |
| N16-12CG-50 | 50 µg | $1,715.12 |
| N16-12CG-500 | 500 µg | $3,788.68 |
General Information
| Validated applications | Kinase Assay |
| Formulation | Supplied as sterile 50 mM Tris-HCl, pH 7.5, 50-300mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25-1.0mM DTT, 0-0.1mM PMSF, 10-25% glycerol Please contact us for any concerns or special requirements. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Shipping | Enzymes are highly recommended to be shipped at frozen temperature with dry ice. Shipment made at ambient temperature may seriously affect the activity of the ordered products. |
| Stability & Storage | Store product at –70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. |
| Purity | For specific information on a given lot, see related technical data sheet. |
| Activity | For specific information on a given lot, see related technical data sheet. |
| Protein Construction | Recombinant human TRKA (G667C) (440-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. |
| Expressed Host | Baculovirus-Insect Cells |
| Species | Human |
| Molecule Mass | ~66 kDa |
| Technical Data Sheet by Lot # | B2180-7 C1875-5 L5144-11 |
Synonyms: MTC Protein, Human; p140-TrkA Protein, Human; TRK Protein, Human; Trk-A Protein, Human; TRK1 Protein, Human; TRKA Protein, Human
Background Information
| Full Name | neurotrophic tyrosine kinase, receptor, type 1 |
| Description | TRKA is a member of the neurotrophic tyrosine kinase receptor (NTKR) family. It is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. Isoform TrkA-III promotes angiogenesis and has oncogenic activity when overexpressed. Isoform TrkA-I is found in most non-neuronal tissues. Isoform TrkA-II is primarily expressed in neuronal cells. TrkA-III is specifically expressed by the pluripotent neural stem and neural crest progenitors. The presence of NTRK1 leads to cell differentiation and may play a role in specifying sensory neuron subtypes. Mutations in the TRKA gene have been associated with congenital insensitivity to pain, anhidrosis, self-mutilating behavior, mental retardation, and cancer. It was originally identified as an oncogene as it is commonly mutated in cancers, particularly colon and thyroid carcinomas. TRKA is required for high-affinity binding to , neurotrophin-3 and neurotrophin-4/5 but not brain-derived neurotrophic factor (BDNF). Known substrates for the Trk receptors are SHC1, PI 3-kinase, and PLC-gamma-1. NTRK1 has a crucial role in the development and function of the nociceptive reception system as well as the establishment of thermal regulation via sweating. It also activates ERK1 by either SHC1- or PLC-gamma-1-dependent signaling pathway. Defects in NTRK1 are a cause of congenital insensitivity to pain with anhidrosis and thyroid papillary carcinoma. |
| Research Areas |
|
| Tags |
|
| References |
|
title: Five-and-six-membered heterocyclic compound and use thereof as protein receptor kinase inhibitor
authors: Lei Jiang; Zhiyong Feng; ...; Yuxing Zhang
date: 2025-08-19
cited_by_count: 0
techniques: Recombinant
bioz_score: 93
title: Discovery of novel indazole derivatives as second-generation TRK inhibitors.
authors: Qiaohua Qin; Shuyu Lu; ...; Maosheng Cheng
journal: European Journal of Medicinal Chemistry
date: 2024-08-09
pmid: 39033612
doi: 10.1016/j.ejmech.2024.116640
cited_by_count: 1
techniques: Concentration Assay; HTRF Assay; Purification
bioz_score: 92
title: Heterocyclic compound as TRK inhibitor
authors: Norman Xianglong Kong; Chao Zhou; Zhixiang Zheng
date: 2024-01-23
cited_by_count: 0
techniques: Activity Assay; Concentration Assay; Control; In Vitro; Inhibition; Kinase Assay; Labeling; Negative Control; Serial Dilution; Software
bioz_score: 93
title: Discovery of novel 3-(1H-pyrazol-4-yl)-1H-indazole derivatives as potent type II TRK inhibitors against acquired resistance.
authors: Qiaohua Qin; Zhiqiang Guo; ...; Maosheng Cheng
journal: European Journal of Medicinal Chemistry
date: 2024-01-01
pmid: 38029466
doi: 10.1016/j.ejmech.2023.115953
cited_by_count: 5
techniques: Concentration Assay; HTRF Assay; Purification
bioz_score: 93
title: Design, synthesis and biological evaluation of novel indolin-2-one derivatives as potent second-generation TRKs inhibitors.
authors: Qiaohua Qin; Qinglin Fu; ...; Maosheng Cheng
journal: European Journal of Medicinal Chemistry
date: 2023-04-25
pmid: 37030091
doi: 10.1016/j.ejmech.2023.115291
cited_by_count: 7
techniques: Concentration Assay; HTRF Assay; Purification
bioz_score: 93
title: Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.
authors: Hiroshi Tanaka; Hitoshi Sase; ...; Toshiyuki Mio
journal: Molecular Cancer Therapeutics
date: 2019-09-10
pmid: 30242093
doi: 10.1158/1535-7163.MCT-17-1180
cited_by_count: 7
techniques: Activity Assay; Binding Assay; Fluorescence; Protein Kinase Assay
bioz_score: 93
title: TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors
authors: Emiliano Cocco; Ji Eun Lee; ...; Maurizio Scaltriti
journal: SSRN Electronic Journal
date: 2019-01-01
doi: 10.2139/ssrn.3501844
cited_by_count: 0
techniques: Clinical Proteomics; Formalin-fixed Paraffin-Embedded; Injection; RNA Sequencing; Recombinant; Sequencing; Software; Virus
bioz_score: 93
MDSD
